The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Nuvisertib in myelofibrosis: targeting PIM1 as a second-line add-on option
Joseph Scandura, MD, PhD, Weill Cornell Medicine, New York, NY, reviews nuvisertib as a second-line treatment option for myelofibrosis. Dr Scandura highlightes the mechanistic benefits of nuvisertib and positions it as a good add-on partner that can add symptom benefit without added toxicity. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
